ArticleEuropean journal of nuclear medicine and molecular imaging2026
Effect of bone marrow disease on hematologic toxicity and response to [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Dosimetry-Driven Personalization of Radiopharmaceutical Therapies: Evidence and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Review
- Tumor microenvironment-mediated hematologic toxicity ofWorld journal of urology · 2026Review
- Baseline PSMA PET/CT Biomarkers for Patient Selection in [Pharmaceuticals (Basel, Switzerland) · 2026Review
- Acute complications of nuclear medicine: an emergency medicine perspective.EJNMMI research · 2026Review
- Artificial intelligence across oncologic theranostics: evidence for patient stratification, dosimetry, and adaptive radiopharmaceutical therapy.Frontiers in nuclear medicine · 2026Review
- Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDespite the effectiveness of [
methodsThis retrospective study included 96 mCRPC patients who underwent pretreatment PSMA-PET/CT and received standard-of-care [
resultsClinically significant hematologic toxicity occurred in 19 patients (19.8%). Treatment discontinuation was more likely in those with a significantly higher (p = 0.007) percentage of total bone volume with PSMA-avid disease (median 28% vs. 1.7%). Those requiring dose delays or reductions (median 21% vs. 1.5%), blood transfusions (median 21% vs. 1.4%), and platelet transfusions (median 32% vs. 1.8%) also exhibited higher median percentages of total bone volume involvement (all p < 0.01). Patients with more heterogeneous PSMA uptake had lower PSA50 response rates than those with more homogeneous uptake (30.3% vs. 64.5%, p = 0.002). A > 50% difference between PSMA-low and PSMA-high bone disease was associated with significantly shorter OS (p < 0.001).
conclusionExtensive PSMA-avid bone involvement was associated with increased hematologic toxicity in mCRPC treated with [
Indexed as
Identifiers
40908334What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.